EPRX•benzinga•
Eupraxia Pharma Announces Treatment Outcomes From Ongoing RESOLVE Phase 1b/2a Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 5, 2025 by benzinga